Date prepared: June 27, 2023<\/p>\n\n\n\n
Abbreviated name of the issuer:<\/p>\n\n\n\n
CELON PHARMA S.A.<\/p>\n\n\n\n
Subject:<\/p>\n\n\n\n
Resolutions adopted by the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023 \u2013 correction<\/p>\n\n\n\n
Legal basis<\/p>\n\n\n\n
Article 56 subs. 1 point 2 of the Act on Public Offering \u2013 current and periodic information<\/p>\n\n\n\n
Content of the report: <\/p>\n\n\n\n
In relation to the receipt of the \u201cProtocol of correction of an obvious mistake in a notarial deed\u201d regarding resolutions adopted at the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023, in which the voting results pertaining to one of the resolutions were corrected, the Management Board hereby presents the corrected information on the resolutions adopted at that Meeting attached herewith. (file: Uchwaly_ZWZ_Celon_Pharma_22.06.2023 skorygowane.pdf)<\/p>\n\n\n\n
The scope of the correction pertains only to the results of vote regarding resolution no. 19.<\/p>\n\n\n\n
The notarial deed previously stated:<\/p>\n\n\n\n
\u201cThe number of shares on which valid votes were cast: 34,852,913.<\/p>\n\n\n\n
the percentage of these shares in the share capital amounts to 68.3%.<\/p>\n\n\n\n
45,264,330 votes were cast in favor of adopting the resolution,<\/p>\n\n\n\n
556,159 votes were cast against,<\/p>\n\n\n\n
4,032,424 votes abstained.<\/p>\n\n\n\n
The notarial deed currently states:<\/p>\n\n\n\n
\u201cThe number of shares on which valid votes were cast: 34,852,913.<\/p>\n\n\n\n
the percentage of these shares in the share capital amounts to 68.3%.<\/p>\n\n\n\n
49,296,754 votes were cast in favor of adopting the resolution,<\/p>\n\n\n\n
556,159 votes were cast against,<\/p>\n\n\n\n
0 votes abstained.<\/p>\n\n\n\n
The remaining scope of the current report No. 17\/2023 remains unchanged:<\/p>\n\n\n\n
The Management Board of Celon Pharma S.A. (\u201cCompany\u201d) hereby publishes the text of the resolutions adopted by the Ordinary General Meeting of the Company on June 22, 2023 and the “Report of the Supervisory Board of Celon Pharma S.A. for the financial year 2022\u201d approved by Resolution No. 7 and the \u201cReport on remuneration of Members of the Management Board and the Supervisory Board of Celon Pharma S.A. for the period 01.01.2021- 31.12.2021”, for which an opinion in the form of Resolution No. 16 was issued.<\/p>\n\n\n\n
During the Ordinary General Meeting, no item on the agenda has been withdrawn and no objection to any of the adopted resolutions has been raised. Since the electronic vote-counting system was used, no resolution on the election of the Returning Committee has been adopted. All resolutions subjected to the vote have been adopted.<\/p>\n","protected":false},"excerpt":{"rendered":"